Siegfried Holding

Capacity Expansions And Advanced Modalities Will Capture Global Pharma Demand

AnalystHighTarget

Not Invested

Consensus Narrative from 10 Analysts

Published

26 Jun 25

Updated

27 Aug 25

AnalystHighTarget's Fair Value

CHF 138.00

38.9% undervalued

27 Aug

CHF 84.30

-24.1%

-0.5%

-24.1%

-0.5%

Author's Valuation

CHF 138.0

38.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CHF 138.0

38.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.56%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.39%

Calculation

CHF 251.61m

Earnings '28

27.45x

PE Ratio '28

CHF 6.91b

Market Cap '28

CHF 6.91b

Market Cap '28

44.45m

No. shares '28

CHF 155.36

Share Price '28

CHF 155.36 Share Price '28

Discounted to 2025 @ 4.39% p.a.

CHF 136.59

Fair Value '25